+972548034532 info@resultmed.com


Caris – Molecular test



Caris Molecular Intelligence is an analysis of a cancerous tumor at the molecular level that helps to make the most detailed profile of the malignant tissue, on the basis of which our oncologists can recommend to the patient drugs actually effective on his tumor, and also to determine the list of drugs that will not be effective.

In order to select an individual effective treatment protocol for your cancer, only genomic mapping (identification of genes responsible for the spread of cancer of the tumor (NGS / Next Generation Sequencing) is not enough. Therefore, it is is recommended a comprehensive molecular study that helps to direct treatment according to your unique genomic and biological characteristics.With a comprehensive analysis of genomic and biological information obtained from your tumor sample, test Caris Molecular Intelligence ® probe finds the molecular “fingerprint” of your tumor. This “fingerprint” is created by identifying biomarkers in your tumor at the level of genetic material (RNA and DNA) and the level of proteins in the tumor that provide extensive information about the tumor’s ability to respond to specific drugs.


Cancer biomarkers are usually proteins, genes and other molecules at the genetic and molecular level that affect the growth of cancer cells, the way they grow and how they react to other compounds in the body.


Due to its quality and innovation Caris test is a confident basis for personalized medicine. It combines extensive laboratory testing with clinical studies on biomarkers to help clinicians evaluate potential drug or clinical benefits as well as adaptation of immunotherapy (Keytruda, Opdivo, Yervoi, etc.). Through gene testing Caris reveals the load of the TML gene and genomic instability in the MSI tumor indices, which help to predict whether a given tumor will respond to immunotherapy.


In addition, proteins are tested in a tumor. Immunohistochemical analysis (IHC), which determines the level of expression of proteins, also includes testing of PD-L1 for immunotherapy. For each patient it is compiled a report which can help doctors to develop a treatment plan for a specific tumor.


Caris benefits


Sample Caris report



What is precision cancer treatment?



Call-Center for an appointment at leading doctors of IsraelContact us if you are not sure about your health condition or diagnosis, if you are faced with the choice of a treatment option, if you need a reliable, clear medical advice of a reputable Israeli doctor, and advanced treatment according to the latest guidelines. We will promptly coordinate an appointment and treatment in Israel.


Tel / Whatsapp / Viber +972 54 803 45 32 info@resultmed.com


ResultMed provides medical treatment coordination for international patients



!מבקרים באתר היקרים, אנא שימו לב

.אנחנו חברה תיירות מרפא. אנו נותנים שרות פרטי לתיירים בלבד

Oncotest CARIS – basis for precision cancer treatment

Caris Molecular Intelligence® is a pioneer in the molecular understanding of cancer, and the basis for precision medicine. This highly developed molecular platform shapes the tumor profile and adjusts treatment options and provides new molecular ideas through a comprehensive study of important genetic material (RNA, DNA) and proteins.

Read More

Caris test benefits

Studies continue to demonstrate the clinical benefits of the multi-technology platform Сaris Molecular Intelligence (CMI), as well as the clinical benefit of composing a molecular “fingerprint” tumor for cancer diagnosis. Clinical benefit is in assisting the physician to choose clinically effective treatments, as well as the positive effect on the overall survival patients with cancer.

Read More



In order to build a molecular imprint of your tumor the test uses a wide range of technologies to identify biomarkers that characterize it:

♦ Immunohistochemistry (IHC / IHC): determines the level of protein expression. Includes PDL1 for immunotherapy.

♦ Next Generation Flooring (NGS): This is a very deep genetic sequencing that examines 592 genes at a depth of 750X. The test detects DNA mutations, variations in the number of copies in gene combinations in the genome, and high depth of coverage makes it extremely sensitive to changes in the genome sequence. In tests with a reading depth of less than 500 X, there is a risk of not detecting mutations in the tumor.♦ In situ Hybridization: identifies gene deletions, maturation, translocations and melting. ♦ Study of genomic instability of MSI and a TML gene load test for the adaptation of immunotherapy.
♦ Pyro Sequence: identifies and quantifies mutations, methylation, etc., using a sequence in the synthesis.
♦ Sequence Sanger: examines DNA strands to detect mutations, by analyzing a long continuous sequence.

♦ Quantitative polymerase chain reaction (qPCR): enhances and quantitatively determines the focused DNA molecule.
♦ FA / Frag Analysis: Identifies changes in DNA-DNA or RNA-RNA to indicate the presence or absence of a genetic marker.

Read More